CYT006-AngQb
Also known as: AngQb, Anti-angiotensin II vaccine, CYT006, CYT006‑AngQb
Source CYT006-AngQb at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
CYT006‑AngQb is an investigational peptide vaccine conjugated to a virus‑like particle carrier (Qb) designed to elicit an immune response against angiotensin II for the treatment of hypertension.
Mechanism of Action
Induces endogenous antibodies that bind and neutralize circulating angiotensin II, thereby reducing vasoconstriction, aldosterone release and blood pressure.
Routes of Administration
Goals & Uses
- Hypertension controlCardiovascularModerate
- Morning blood pressure surge attenuationCardiovascularModerate
- Long-term antihypertensive control with infrequent dosingCardiovascular / AdherenceLow
- Blood pressure reduction in arterial hypertensionCardiovascularModerate
Contraindications
- Immunocompromised stateImmuneModerate
- Autoimmune diseaseImmuneModerateMay worsen or interact with immune-mediated disease
- Severe renal artery stenosisRenal/VascularHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Known hypersensitivity to vaccine components or bacteriophage proteinsImmunologicalHigh
- Severe hypotensionCardiovascularHigh
Adverse Effects
- Flu-like symptomsSystemic/ImmunologicalCommon
- Mild hypotensionSystemicUncommon
- Flu‑like symptomsSystemicUncommon
- Injection site reactionsLocalCommon
- Injection‑site painLocalCommon
- HypotensionCardiovascularUncommonLow blood pressure
- Renal function impairmentRenalRare
Drug Interactions
- Angiotensin‑II receptor blockers (ARBs)Moderate
- Angiotensin Receptor Blockers (ARBs)Moderate
- ACE inhibitorsModerate
- DiureticsLowMay worsen dehydration or electrolyte imbalance
- ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk
- Potassium-sparing diureticsModerate
Population Constraints
- Pediatric patientsAgeAbsolute
- Children (<18 y)AgeAbsolute
- Pregnant or lactating womenReproductiveAbsolute
- Immunocompromised patientsImmunologicRelative
- Pregnant womenReproductiveAbsolute
- Patients with severely compromised renal functionRenalRelative
Regulatory Status
- European UnionInvestigationalUnder clinical evaluation; not authorized by EMA.
- United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval.
- United KingdomInvestigationalClinical trial material; no MHRA marketing authorization.
Completed Phase II trials in several countries; not approved by FDA, EMA or MHRA.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is CYT006-AngQb?
CYT006‑AngQb is an investigational peptide vaccine conjugated to a virus‑like particle carrier (Qb) designed to elicit an immune response against angiotensin II for the treatment of hypertension.
What is CYT006-AngQb used for?
CYT006-AngQb is educationally associated with: Hypertension control, Morning blood pressure surge attenuation, Long-term antihypertensive control with infrequent dosing, Blood pressure reduction in arterial hypertension. Educational only — not medical advice.
How is CYT006-AngQb administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of CYT006-AngQb?
Reported adverse effects include: Flu-like symptoms, Mild hypotension, Flu‑like symptoms, Injection site reactions, Injection‑site pain, Hypotension, Renal function impairment. This list is not exhaustive — consult a qualified clinician.
Who should avoid CYT006-AngQb?
Recorded contraindications: Immunocompromised state, Autoimmune disease, Severe renal artery stenosis, Pregnancy, Known hypersensitivity to vaccine components or bacteriophage proteins, Severe hypotension. Consult a qualified clinician before use.